JD Health International stock
6618.HKHKSEJD Health International Inc., HealthcareISIN KYG5074A1004
70Score 70 out of 100, Strong
Price and trend
60 / 100
Price history
−37% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 5.6% below it.
Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 63).
The price is 42% below its 52-week high. Largest decline in 6 years: 90% (December 2020 to August 2024).
Chart figures for advanced users
- SMA 50$4.74
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.47
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)63
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.06
- The lowest closing price of the last twelve months.
- Resistance$8.84
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- JD Health International Inc. belongs to the Medical (Pharmaceuticals) industry (China) and, with a market value of $16.47B, is number 3 of 15 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $11.01B (up 26.3% year on year) and earnings of $806.12M (up 29.2%).
- MEQIRI Score 70 out of 100 (Strong): rank 120 of 702 in Healthcare, median 53.
Show more
- The P/E is 17.9 (Medical (Pharmaceuticals) median 21.2, own median of recent years 29.7).
- Our model puts fair value at $7.54, with the price 31% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 30.5% a year since 2020, Healthcare sector median 12.1%.Growth 78
- High return on capitalReturn on invested capital 40.1% in fiscal 2025, Healthcare sector median 9.2%.Profitability 57
- More cash than debtCash $7.11B, financial debt $131.17M.Stability 85
Weaknesses
- DilutionShare count up 45% since 2020.
- Share price fell sharplyDown 32% over the last 12 months.Momentum 36
Its standout strengths are fundamentals and stability, while momentum holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedClosing price of 12 Nov 2026, used by the daily score.
In our model the price counts as cheap below $5.38 and expensive above $12.56 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $8.95 (cash-flow model) and $6.12 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.6%. At 8.6% the fair value would be $6.85, at 6.6% it would be $8.54.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.2).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 20.5% on the twelve months before. Revenue has grown strongly since 2017, at around 38% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 25%, operating 5%, net 7%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 29 Mar 2027in 136 days
- Last reported
- 13 Aug 2026EPS reported 1.24 (expected 1.35)below expectations
Analyst estimates
Earnings estimates have barely changed since 24 Oct 2026.
- Earnings per share
- 1.93+1.6%
- Revenue
- $13.07B+0.2%
- Earnings per share
- 2.29+1.7%
- Revenue
- $15.09B+0.5%
MEQIRI has stored the estimates since 24 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at JD Health International
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Pharmaceuticals)
The next larger and next smaller companies by market value
- Royalty PharmaRPRX $30.71B71
- Swedish Orphan BiovitrumSOBI.ST $16.99B75
- Sino Biopharmaceutical1177.HK $12.58B65
- Recordati Industria Chimica e FarmaceuticaREC.MI $11.92B74
- Kyowa Kirin4151.T $8.4B77
- Corcept TherapeuticsCORT $8.07B75
- Kiniksa Pharmaceuticals InternationalKNSA $7.56B68
- Tsuruha Holdings3391.T $7.1B62
ETFs that hold JD Health International
Held by 59 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 2.99% | 0.68% | €5.31M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.81% | 0.49% | €318.64M |
| EMQQ Emerging Markets Internet UCITS ETF AccEMQQ | 0.50% | 0.86% | €87.18M |
Show 5 more
| Amundi MSCI China ESG Selection Extra UCITS ETF DistLHKG | 0.45% | 0.65% | €564.13M |
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.37% | 0.30% | €132.6M |
| iShares BIC 50 UCITS ETFIQQ9 | 0.30% | 0.74% | €98.42M |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.27% | 0.60% | €31.52M |
| Deka MSCI China ex A Shares UCITS ETFEL46 | 0.24% | 0.65% | €73.86M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Undervalued since 12 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.